Compare Sana Biotechnology Inc (SANA) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs J M Smucker Co — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $947.48M), while J M Smucker Co trades at $123.61 (market cap $13.17B). The key difference: J M Smucker Co is far larger — about 13.9× Sana Biotechnology Inc's market cap, and J M Smucker Co pays a 3.63% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | SJM | |
|---|---|---|
Market Cap | $947.48M | $13.17B |
Sector | Health | Consumer Staples |
52-Week High | $5.92 | $132.34 |
52-Week Low | $2.68 | $89.53 |
Enterprise Value | $860.73M | $20.03B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
SJM trades at $124.66, down 1.13% on the day, with a bullish technical signal from moving averages but bearish oscillators. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $3.24 surpassing the $2.22 estimate. The company reported a net loss of $1.23 billion for 2025, though revenue grew to $8.73 billion. Analyst consensus is a Buy with a $144.78 price target, indicating potential upside. A dividend of $1.12 per share is scheduled for payment on September 1, 2026.
The outlook is cautiously optimistic, driven by strong earnings performance and raised guidance, but high valuation ratios and recent insider sales pose risks. Debt levels remain elevated with a debt-to-asset ratio of 43.71% in 2025. Investors should weigh robust operational cash flow against margin pressures and competitive challenges in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
